Ocumetics Director and CEO, Dean Burns, walks through relevant topics including:
- Manufacturing of the Ocumetics IOL
- Journey to first-in-human study
- Q&A session
Thanks to everyone who joined us for the Webinar. It was an amazing turnout, and it was great to hear your questions and comments. We look forward to hosting more webinars in the future!
https://youtu.be/4zxDK3kSSYE?si=omXiuekk30ZBqHgn
Calgary, Alberta – February 10, 2026 – TheNewswire – Ocumetics Technology Corp. (“Ocumetics” or the “Corporation”) (TSXV: OTC) (OTCQB: OTCFF) (FRA: 2QBO) is pleased to announce that the Corporation has entered into a forbearance agreement with the holders of secured convertible debentures (the “Debentures”) that were issued by the Corporation in May and June 2024 (see press release
Calgary, AB – TheNewswire – January 2, 2026 – Ocumetics Technology Corp. (“Ocumetics” or the “Corporation”) (TSXV: OTC) (OTCQB: OTCFF) (FRA: 2QB0) is pleased to announce that it has closed the first tranche of its previously announced best efforts brokered private placement of units of the Company (the “Units”) for aggregate gross proceeds of approximately
Calgary, AB – TheNewswire – December 19, 2025 – Ocumetics Technology Corp. (“Ocumetics” or the “Corporation”) (TSXV: OTC) (OTCQB: OTCFF) (FRA: 2QB0) announces that further to its previously announced (November 25, 2025) brokered private placement (the “Offering”) on a best-efforts basis led by Centurion One Capital Corp. (the “Lead Agent”), the Corporation has amended the
